By Chris Wack
Tyme Technologies Inc. said it has received notification that the U.S. Patent and Trademark Office has granted additional patent claims related to its metabolomic technology platform.
The biotechnology company said the patent involves a targeted delivery of therapeutics to cancer cells.
Tyme said it has developed a technology by which the tyrosine isomer racemetyrosine can be fused with a second therapeutic agent in a manner that creates a fusion compound that may allow targeted delivery to the cancer cells in a novel manner.
This method of delivery is predicated on the metabolic phenomenon in which cancer cells consume higher quantities of non-essential amino acids, including tyrosine, from their surrounding environment to support their growth because they cannot make enough of these amino acids.
The delivery technology is an investigational method of drug delivery in the pre-clinical phase of development that isn’t approved in the U.S. for any disease indication and requires further studies, which the company plans to initiate this year.
Tyme shares were up 22%, to $1.32, in premarket trading.
Write to Chris Wack at [email protected]